Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 314
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04623710 | Study of ALXN2050 in Participants With Renal Impairment | ||
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease | ||
| NCT02207725 | A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban | ||
| NCT07789483 | An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy | ||
| NCT02112994 | Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency | ||
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) | ||
| NCT02128269 | Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome | ||
| NCT03759366 | A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) | ||
| NCT01095887 | Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation | ||
| NCT03403205 | Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease | ||
| NCT01522183 | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry | ||
| NCT02226146 | Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid | ||
| NCT04560816 | A Study of the Cardiac Effects of ALXN1840 in Healthy Adults | ||
| NCT02293408 | Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB | ||
| NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | ||
| NCT00485576 | Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma | ||
| NCT01180790 | Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants | ||
| NCT07413679 | Long-term Safety of Danicopan: IPIG Registry-based Cohort Study | ||
| NCT07413250 | Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data | ||
| NCT03613402 | BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes | ||
| NCT01203826 | Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP) | ||
| NCT05389449 | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | ||
| NCT00122317 | Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT02113891 | Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation | ||
| NCT04725812 | Complement Regulation to Undo Systemic Harm in Preeclampsia | ||
| NCT02946463 | ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT03131219 | Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT00438789 | The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol | ||
| NCT02235493 | Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09 | ||
| NCT02245412 | A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease | ||
| NCT03723512 | Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study | ||
| NCT06764160 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG | ||
| NCT05419765 | Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease | ||
| NCT01192399 | Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients | ||
| NCT06578949 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT05876351 | Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China | ||
| NCT03661528 | Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor | ||
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | ||
| NCT05254613 | A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants | ||
| NCT00744042 | Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP) | ||
| NCT02949128 | Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT00739505 | Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP) | ||
| NCT05686564 | Early Access Program for ALXN1840 in Patients With Wilson Disease | ||
| NCT04757259 | Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib | ||
| NCT02306720 | Registry of Patients With Hypophosphatasia | ||
| NCT05683678 | US Selumetinib Registry | ||
| NCT04970004 | Study in Adult and Pediatric Patients With HSCT-TMA | ||
| NCT06744647 | Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation | ||
| NCT04369469 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | ||
| NCT00844428 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS |
